Communiqués Nkarta, Inc.

Actions

NKTX

US65487U1088

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/06/2024			Varia. 5j.	Varia. 1 janv.
5,97 ^USD	-2,61 %		+13,28 %	-9,55 %

12:00	Nkarta, Inc. lance un essai clinique sur le NKX019 dans le lupus néphrétique avec un premier patient en dépistage et annonce l'élargissement de son portefeuille à d'autres indications auto-immunes	CI
13/06	Nkarta, Inc. nomme George Vratsanos au conseil d'administration	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications	12:00	AQ
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors	13/06	AQ
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights	09/05	AQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors	08/04	BU
Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors	05/04	BU
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors	05/04	BU
Nkarta to Participate in Upcoming Investor Conferences	03/04	AQ
Nkarta Announces Pricing of $240 Million Underwritten Offering	25/03	AQ
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights	21/03	AQ
Nkarta to Participate in Upcoming Investor Conferences	28/02	AQ
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition	10/12	AQ
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights	09/11	AQ
Nkarta to Participate at Upcoming Investor Conferences	07/11	AQ
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer Cell Therapy in Lupus Nephritis	18/10/23	AQ
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis	17/10/23	AQ
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures	16/10/23	AQ
Rezo Therapeutics Appoints Nadir Mahmood, Ph.D., as Chief Executive Officer	21/09/23	AQ
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights	10/08/23	AQ
Nkarta to Participate at Upcoming Investor Conference	03/08/23	AQ
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer	05/07/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Nkarta, Inc.

Actions

NKTX

US65487U1088

Communiqués

Filtres